<DOC>
	<DOCNO>NCT02345252</DOCNO>
	<brief_summary>This study evaluate safety efficacy emtricitabine/rilpivirine/tenofovir alafenamide ( FTC/RPV/TAF ) fixed-dose combination ( FDC ) versus continue emtricitabine/rilpivirine/tenofovir disoproxil fumarate ( FTC/RPV/TDF ) FDC HIV-1 infect adult virologically suppress stable regimen FTC/RPV/TDF ≥ 6 consecutive month prior screen .</brief_summary>
	<brief_title>Switch Study Evaluate Safety Efficacy Emtricitabine/Rilpivirine/Tenofovir Alafenamide ( FTC/RPV/TAF ) Fixed Dose Combination ( FDC ) HIV-1 Positive Adults Who Are Virologically Suppressed Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate ( FTC/RPV/TDF )</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Key The ability understand sign write informed consent form , must obtain prior initiation study procedure Currently receive FTC/RPV/TDF FDC ≥ 6 consecutive month precede screen visit Documented plasma HIV1 RNA level &lt; 50 copies/mL ( undetectable HIV1 RNA level accord local assay use limit detection &gt; 50 copies/mL ) ≥ 6 month precede screen visit . After reach HIV1 RNA &lt; 50 copies/mL , single value HIV1 RNA ≥ 50 copies/mL follow resuppression , allow Have document resistance study agent time past HIV1 RNA &lt; 50 copies/mL screen visit Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL ( ≤ 26μmol/L ) , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm^3 ( 1.00 GI/L ) ; platelet ≥50,000/mm^3 ( 50 GI/L ) ; hemoglobin ≥ 8.5 g/dL ( 85 g/L ) ) Serum amylase ≤ 5 × ULN ( individual serum amylase &gt; 5 × ULN remain eligible serum lipase ≤ 5 × ULN ) Normal ECG ( abnormal , determined Investigator clinically significant ) Adequate renal function : Estimated glomerular filtration rate ≥ 50 mL/min ( 1.17 mL/sec ) accord CockcroftGault formula Key Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C antibody positive detectable hepatitis C virus ( HCV ) RNA ( individual HCV antibody detectable HCV RNA eligible enroll ) Individuals experience medical history decompensated cirrhosis ( e.g. , ascites , encephalopathy , etc . ) Females breastfeed Positive serum pregnancy test Current alcohol substance use judge Investigator potentially interfere subject study compliance A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Individuals cutaneous KS eligible , must receive systemic therapy KS within 30 day Baseline/Day 1 must anticipate require systemic therapy study Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Baseline/Day 1 Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval sponsor prohibit participate trial Individuals receive ongoing therapy follow medication table , include drug use FTC , RPV and/or TAF ( refer individual agent Prescribing Information ) ; individual know allergy excipients FTC/RPV/TAF Note : Other Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
</DOC>